Chronic endothelin receptor blockade reduces end-organ damage independently of blood pressure effects in salt-loaded heterozygous Ren-2 transgenic rats
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
15588125
Knihovny.cz E-resources
- MeSH
- Endothelin Receptor Antagonists * MeSH
- Administration, Oral MeSH
- Bosentan MeSH
- Sodium Chloride administration & dosage MeSH
- Animals, Genetically Modified MeSH
- Hypertension complications physiopathology MeSH
- Blood Pressure * MeSH
- Rats MeSH
- Survival Rate MeSH
- Multiple Organ Failure etiology physiopathology MeSH
- Rats, Sprague-Dawley MeSH
- Receptors, Endothelin metabolism MeSH
- Renin-Angiotensin System drug effects MeSH
- Renin genetics metabolism MeSH
- Severity of Illness Index MeSH
- Sulfonamides administration & dosage MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Endothelin Receptor Antagonists * MeSH
- Bosentan MeSH
- Sodium Chloride MeSH
- Receptors, Endothelin MeSH
- Ren2 protein, mouse MeSH Browser
- Renin MeSH
- Sulfonamides MeSH
The present study was performed to evaluate the role of an interaction between the endothelin (ET) and the renin-angiotensin systems (RAS) in the development and maintenance of hypertension and in hypertension-associated end-organ damage in heterozygous male and female transgenic rats harboring the mouse Ren-2 renin gene (TGR). Twenty-eight days old heterozygous TGR and age-matched transgene-negative normotensive Hannover Sprague-Dawley rats (HanSD) were randomly assigned to groups with normal-salt (NS) or high-salt (HS) intake. Nonselective ET(A)/ET(B) receptor blockade was achieved with bosentan (100 mg.kg(-1).day(-1)). All male and female HanSD as well as heterozygous TGR on NS exhibited 100 % survival rate until 180 days of age (end of experiment). HS diet in heterozygous TGR induced a transition from benign to malignant phase hypertension. The survival rates in male and in female heterozygous TGR on the HS diet were 46 % and 80 %, respectively, and were significantly improved by administration of bosentan to 76 % and 97 %, respectively. Treatment with bosentan did not influence either the course of hypertension (measured by plethysmography in conscious animals) or the final levels of blood pressure (measured by a direct method in anesthetized rats) in any of the experimental groups of HanSD or TGR. Administration of bosentan in heterozygous TGR fed the HS diet markedly reduced proteinuria, glomerulosclerosis and attenuated the development of cardiac hypertrophy compared with untreated TGR. Our data show that the ET receptor blockade markedly improves the survival rate and ameliorates end-organ damage in heterozygous TGR exposed to HS diet. These findings indicate that the interaction between the RAS and ET systems plays an important role in the development of hypertension-associated end-organ damage in TGR exposed to salt-loading.
Hypertension after the Menopause: What Can We Learn from Experimental Studies?